Literature DB >> 26800240

Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.

Daisy P F Tsang1,2, William K K Wu1,3, Wei Kang4, Ying-Ying Lee1,2, Feng Wu4, Zhuo Yu1, Lei Xiong4, Anthony W Chan4, Joanna H Tong4, Weiqin Yang1,2, May S M Li1,5, Suki S Lau1, Xiangchun Li1,2, Sau-Dan Lee6, Yihua Yang7, Paul B S Lai1,8, Dae-Yeul Yu9, Gang Xu2, Kwok-Wai Lo4, Matthew T V Chan3, Huating Wang7, Tin L Lee5, Jun Yu1,2, Nathalie Wong1,4, Kevin Y Yip6, Ka-Fai To1,4, Alfred S L Cheng1,5.   

Abstract

Enhancer of zeste homolog 2 (EZH2) catalyses histone H3 lysine 27 trimethylation (H3K27me3) to silence tumour-suppressor genes in hepatocellular carcinoma (HCC) but the process of locus-specific recruitment remains elusive. Here we investigated the transcription factors involved and the molecular consequences in HCC development. The genome-wide distribution of H3K27me3 was determined by chromatin immunoprecipitation coupled with high-throughput sequencing or promoter array analyses in HCC cells from hepatitis B virus (HBV) X protein transgenic mouse and human cell models. Transcription factor binding site analysis was performed to identify EZH2-interacting transcription factors followed by functional characterization. Our cross-species integrative analysis revealed a crucial link between Yin Yang 1 (YY1) and EZH2-mediated H3K27me3 in HCC. Gene expression analysis of human HBV-associated HCC specimens demonstrated concordant overexpression of YY1 and EZH2, which correlated with poor survival of patients in advanced stages. The YY1 binding motif was significantly enriched in both in vivo and in vitro H3K27me3-occupied genes, including genes for 15 tumour-suppressive microRNAs. Knockdown of YY1 reduced not only global H3K27me3 levels, but also EZH2 and H3K27me3 promoter occupancy and DNA methylation, leading to the transcriptional up-regulation of microRNA-9 isoforms in HCC cells. Concurrent EZH2 knockdown and 5-aza-2'-deoxycytidine treatment synergistically increased the levels of microRNA-9, which reduced the expression and transcriptional activity of nuclear factor-κB (NF-κB). Functionally, YY1 promoted HCC tumourigenicity and inhibited apoptosis of HCC cells, at least partially through NF-κB activation. In conclusion, YY1 overexpression contributes to EZH2 recruitment for H3K27me3-mediated silencing of tumour-suppressive microRNAs, thereby activating NF-κB signalling in hepatocarcinogenesis.
Copyright © 2016 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  ChIP-seq; DNA methylation; EZH2; histone modification; liver cancer

Mesh:

Substances:

Year:  2016        PMID: 26800240     DOI: 10.1002/path.4688

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  25 in total

1.  YY1 promotes colorectal cancer proliferation through the miR-526b-3p/E2F1 axis.

Authors:  Zejun Fang; Hua Yang; Dan Chen; Xiaoying Shi; Qinqiu Wang; Chaoju Gong; Xi Xu; Hong Liu; Min Lin; Junxiao Lin; Chengfu Xu; Jimin Shao
Journal:  Am J Cancer Res       Date:  2019-12-01       Impact factor: 6.166

Review 2.  Super-Enhancers, Phase-Separated Condensates, and 3D Genome Organization in Cancer.

Authors:  Seng Chuan Tang; Udhaya Vijayakumar; Ying Zhang; Melissa Jane Fullwood
Journal:  Cancers (Basel)       Date:  2022-06-10       Impact factor: 6.575

3.  Computational characterization of chromatin domain boundary-associated genomic elements.

Authors:  Seungpyo Hong; Dongsup Kim
Journal:  Nucleic Acids Res       Date:  2017-10-13       Impact factor: 16.971

Review 4.  Polycomb repressive complex's evolutionary conserved function: the role of EZH2 status and cellular background.

Authors:  Koraljka Gall Trošelj; Renata Novak Kujundzic; Djurdjica Ugarkovic
Journal:  Clin Epigenetics       Date:  2016-05-27       Impact factor: 6.551

Review 5.  Epigenetic Activation of Wnt/β-Catenin Signaling in NAFLD-Associated Hepatocarcinogenesis.

Authors:  Yuan Tian; Myth T S Mok; Pengyuan Yang; Alfred S L Cheng
Journal:  Cancers (Basel)       Date:  2016-08-20       Impact factor: 6.639

6.  Upregulation of miR-146a by YY1 depletion correlates with delayed progression of prostate cancer.

Authors:  Yeqing Huang; Tao Tao; Chunhui Liu; Han Guan; Guangyuan Zhang; Zhixin Ling; Lei Zhang; Kai Lu; Shuqiu Chen; Bin Xu; Ming Chen
Journal:  Int J Oncol       Date:  2017-01-05       Impact factor: 5.650

7.  YY1 promotes HDAC1 expression and decreases sensitivity of hepatocellular carcinoma cells to HDAC inhibitor.

Authors:  Sheng Dong; Xiang Ma; Zusen Wang; Bing Han; Hao Zou; Zehua Wu; Yunjin Zang; Likun Zhuang
Journal:  Oncotarget       Date:  2017-06-20

8.  Diagnostic and prognostic relevance of CP2c and YY1 expression in hepatocellular carcinoma.

Authors:  Ji Sook Kim; Seung Han Son; Min Young Kim; DongHo Choi; Ik-Soon Jang; Seung Sam Paik; Ji Hyung Chae; Vladimir N Uversky; Chul Geun Kim
Journal:  Oncotarget       Date:  2017-04-11

Review 9.  The Role of Transcription Factor YY1 in the Biology of Cancer.

Authors:  Neeraj Agarwal; Dan Theodorescu
Journal:  Crit Rev Oncog       Date:  2017

10.  Multifaceted regulation of hepatic lipid metabolism by YY1.

Authors:  Gang Pan; Klev Diamanti; Marco Cavalli; Ariadna Lara Gutiérrez; Jan Komorowski; Claes Wadelius
Journal:  Life Sci Alliance       Date:  2021-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.